10 molecular testing shifts defining oncology outcomes in 2026 The dawn of 2026 marks a transformative period for precision oncology as global health systems transition toward mandatory genomic profiling for early-stage malignancies. Under the latest WHO-aligned diagnostic frameworks, clinicians are no longer viewing biomarkers as optional data points but as the foundational architecture for...

Cancer treatment has changed dramatically over the last decade, and precision medicine is a huge reason why. Instead of generalized chemotherapy, doctors now use genetic profiling to identify mutations and target them directly. The US Precision Medicine Market is booming as oncology becomes one of its strongest application areas. With the support of genomic sequencing, physicians can now match...

Personalized healthcare isn’t just a buzzword anymore — it’s actually transforming treatment strategies worldwide. Instead of generalized drug prescriptions, clinicians now rely on genetic testing and biomarker analysis to guide therapy. This approach improves patient outcomes while minimizing unnecessary side effects. Recent data shows the Precision Medicine...